Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients

Ritonavir-boosted saquinavir (SQV/r) is currently licensed as a twice-daily regimen. Reducing the pill burden with once-daily dosing may improve adherence. Intracellular concentrations of drugs must be related to the clinical efficacy of protease inhibitors. The aims of the study were to determine t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ford, Jennifer, Boffito, Marta, Wildfire, Adrian, Hill, Andrew, Back, David, Khoo, Saye, Nelson, Mark, Moyle, Graeme, Gazzard, Brian, Pozniak, Anton
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2004
Materias:
Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC434222/
https://ncbi.nlm.nih.gov/pubmed/15215085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.7.2388-2393.2004
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares